Use of Inhaled Tobramycin in Cystic Fibrosis

Advances in Therapy

Volumn 32, Issue 1, 2015, Pages 1-9

  Shteinberg, Michal ^a,b   Elborn, J Stuart ^b  

^a CARMEL MEDICAL CENTER   (Israel)

^b QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

Cystic fibrosis; Dry powder inhalation; Pseudomonas aeruginosa; Tobramycin

Indexed keywords

TOBRAMYCIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC THERAPY; BACTERIAL CLEARANCE; CYSTIC FIBROSIS; DRUG EFFICACY; DRY POWDER; DRY POWDER INHALER; HUMAN; INFECTION CONTROL; LUNG INFECTION; NEBULIZER; NONHUMAN; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTION; RESPIRATORY TRACT INFECTION; REVIEW; COMPLICATION; DRUG EFFECTS; INHALATIONAL DRUG ADMINISTRATION; ISOLATION AND PURIFICATION; LUNG FUNCTION TEST; PROCEDURES; PSEUDOMONAS INFECTIONS; PSYCHOLOGY; QUALITY OF LIFE; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-BACTERIAL AGENTS; CYSTIC FIBROSIS; DRY POWDER INHALERS; HUMANS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS; QUALITY OF LIFE; RESPIRATORY FUNCTION TESTS; TOBRAMYCIN; TREATMENT OUTCOME;

EID: 84925460985     PISSN: 0741238X     EISSN: 18658652     Source Type: Journal    
DOI: 10.1007/s12325-015-0179-3     Document Type: Review

References (41)

1. Boucher RC, Knowles MR, Yankaskas JR. Cystic Fibrosis. In: Mason: Murray and Nadel’s Textbook of Respiratory Medicine, 5th ed. Saunders: Elsevier; 2010.
2. Viviani L, Zolin A, Olesen HV, et al. ECFSPR Annual Report 2008–2009. 2012. https://www.ecfs.eu/projects/ecfs-patient-registry/annual-reports.
3. Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Pulmonary Clinical Practice Guidelines Committee. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680–9.
4. Tunney MM, Field TR, Moriarty TF, et al. Detection of anaerobic bacteria in high numbers in sputum from patients with cystic fibrosis. Am J Respir Crit Care Med. 2008;177:995–1001.
5. Fodor AA, Klem ER, Gilpin DF, et al. The adult cystic fibrosis airway microbiota is stable over time and infection type, and highly resilient to antibiotic treatment of exacerbations. PLoS One. 2012;7:e45001.
6. Emerson J, Rosenfeld M, McNamara S, Ramsey B, Gibson RL. Pseudomonas aeruginosa and other predictors of mortality and morbidity in young children with cystic fibrosis. Pediatr Pulmonol. 2002;34:91–100.
7. Høiby N, Frederiksen B. Microbiology. In: Hodson ME, Geddes D, editors. Cystic fibrosis. London: Arnold; 2000. p. 83–108.
8. Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol. 2001;32:277–87.
9. Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol. 1992;12:158–61.
10. Craig W. Tobramycin. In: Suzanne Crowe, James McCarthy, editors. Use of antibiotics: a clinical review of antibacterial agents, 6th ed. John Mills, Taylor & Francis; 2010. pp. 699–711.
11. Geller DE, Pitlick WH, Nardella PA, Tracewell WG, Ramsey BW. Pharmacokinetics and bioavailability of aerosolized tobramycin in cystic fibrosis. Chest. 2002;122:219–26.
12. Nikolaizik WH, Trociewicz K, Ratjen F. Bronchial reactions to the inhalation of high-dose tobramycin in cystic fibrosis. Eur Respir J. 2002;20(1):122–6.
13. Ratjen F, Munck A, Kho P, Angyalosi G, ELITE Study Group. Treatment of Early Pseudomonas aeruginosa infection in patients with cystic fibrosis: The ELITE Trial. Thorax. 2010;65:286–91.
14. Treggiari MM, Retsch-Bogart G, Mayer-Hamblett N, et al. Comparative efficacy and safety of 4 randomized regimens to treat early Pseudomonas aeruginosa infection in children with cystic fibrosis. Arch Pediatr Adolesc Med. 2011;165:847–56.
15. Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K. Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis. J Cyst Fibros. 2013;12:29–34.
16. Taccetti G, Bianchini E, Cariani L, et al. Early antibiotic treatment for Pseudomonas aeruginosa eradication in patients with cystic fibrosis: a Randomised Multicentre Study Comparing Two Different Protocols. Thorax. 2012;67:853–9.
17. Langton Hewer SC, Smyth AR. Antibiotic strategies for eradicating Pseudomonas aeruginosa in people with cystic fibrosis. Cochrane Database Syst Rev. 2009:CD004197.
18. Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med. 1993;328:1740–6.
19. Eisenberg J, Pepe M, Williams-Warren J, et al. A comparison of peak sputum tobramycin concentration in patients with cystic fibrosis using jet and ultrasonic nebulizer systems. Chest. 1997;111:955–62.
20. Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med. 1999;340:23–30.
21. Slattery DM, Zurakowski D, Colin AA, Cleveland RH. CF: an x-ray database to assess effect of aerosolized tobramycin. Pediatr Pulmonol. 2004;38:23–30.
22. Hodson ME, Gallagher CG, Govan JRW. A randomised clinical trial of nebulised tobramycin or colistin in cystic fibrosis. Eur Respir J. 2002;20:658–64.
23. Adeboyeku D, Scott S, Hodson ME. Open follow-up study of tobramycin nebuliser solution and colistin in patients with cystic fibrosis. J Cyst Fibros. 2006;5(4):261–3.
24. Schuster A, Haliburn C, Döring G, Goldman MH, Freedom Study Group. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax. 2013;68:344–50.
25. Murphy TD, Anbar RD, Lester LA, et al. Treatment with tobramycin solution for inhalation reduces hospitalizations in young CF subjects with mild lung disease. Pediatr Pulmonol. 2004;38:314–20.
26. Chalmers JD, Goeminne P, Aliberti S, et al. The bronchiectasis severity index. An International Derivation and Validation Study. Am J Respir Crit Care Med. 2014;189:576–85.
27. Drobnic ME, Suñé P, Montoro JB, Ferrer A, Orriols R. Inhaled tobramycin in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection with Pseudomonas aeruginosa. Ann Pharmacother. 2005;39:39–44.
28. Orriols R, Roig J, Ferrer J. Inhaled antibiotic therapy in non-cystic fibrosis patients with bronchiectasis and chronic bronchial infection by Pseudomonas aeruginosa. Respir Med. 1999;93:476–80.
29. Barker AF, Couch L, Fiel SB, et al. Tobramycin solution for inhalation reduces sputum Pseudomonas aeruginosa density in bronchiectasis. Am J Respir Crit Care Med. 2000;162:481–5.
30. Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest. 2005;127:1420–6.
31. Flume PA, O’Sullivan BP, Robinson KA, et al. Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2013;187:680–9.
32. Kerem E, Conway S, Elborn S, Heijerman H, Consensus Committee. Standards of care for patients with cystic fibrosis: a European consensus. J Cyst Fibros. 2005;4:7–26.
33. Döring G, Flume P, Heijerman H, Elborn JS, Consensus Study Group. Treatment of lung infection in patients with cystic fibrosis: current and future strategies. J Cyst Fibros. 2012;11:461–79.
34. Lenney W, Edenborough F, Kho P, Kovarik JM. Lung deposition of inhaled tobramycin with eFlow rapid/LC Plus jet nebuliser in healthy and cystic fibrosis subjects. J Cyst Fibros. 2011;10:9–14.
35. Geller DE, Weers J, Heuerding S. Development of an inhaled dry-powder formulation of tobramycin using PulmoSphereTM Technology. J Aerosol Med Pulm Drug Deliv. 2011;24:175–82.
36. Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety. Pediatr Pulmonol. 2007;42:307–13.
37. Konstan MW, Geller DE, Minić P, Brockhaus F, Zhang J, Angyalosi G. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: The EVOLVE Trial. Pediatr Pulmonol. 2011;46:230–8.
38. Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER Trial. J Cyst Fibros. 2011;10:54–61.
39. Briesacher BA, Quittner AL, Saiman L, Sacco P, Fouayzi H, Quittell LM. Adherence with tobramycin inhaled solution and health care utilization. BMC Pulm Med. 2011;11:5.
40. Electronic Medicine Compendium. http://www.medicines.org.uk/emc/.
41. Cystic Fibrosis Trust. UK Cystic Fibrosis Registry Annual data report 2013. 2013. http://www.cysticfibrosis.org.uk/research-care/uk-cf-registry.